Literature DB >> 2271373

Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism.

J Sonne1, S Boesgaard, H E Poulsen, S Loft, J M Hansen, M Døssing, F Andreasen.   

Abstract

1. The effect of severe hypothyroidism on the pharmacokinetics and pharmacodynamics of oxazepam 15 mg given orally (n = 10) and the metabolism of paracetamol 750 mg given intravenously (n = 8) was investigated before and after treatment with levothyroxine. 2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01). 3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05). 4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid. 5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01). This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1. 6. Hypothyroidism was associated with decreased performance in a finger tapping test that was exacerbated by oxazepam. When the patients were euthyroid oxazepam did not produce any effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2271373      PMCID: PMC1368175          DOI: 10.1111/j.1365-2125.1990.tb03844.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Influence of thyroid status on plasma half-life of antipyrine in man.

Authors:  M Eichelbaum; G Bodem; R Gugler; D Schneider-Deters; H J Dengler
Journal:  N Engl J Med       Date:  1974-05-09       Impact factor: 91.245

2.  Unaltered metabolism of phenytoin in thyroid disorders.

Authors:  J Mølholm Hansen; L Skovsted; J P Kampmann; B I Lumholtz; K Siersbaek-Nielsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-05

Review 3.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

4.  Bioavailability and pharmacokinetics of oxazepam.

Authors:  J Sonne; S Loft; M Døssing; A Vollmer-Larsen; K L Olesen; M Victor; F Andreasen; P B Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Altered plasma protein binding of drugs in thyroid disease.

Authors:  J Feely; I H Stevenson; J Crooks
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

6.  Oxazepam kinetics: effects of age and sex.

Authors:  D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1980-10       Impact factor: 4.030

7.  Phenobarbital induction does not potentiate hepatotoxicity but accelerates liver cell necrosis from acetaminophen overdose in the rat.

Authors:  H E Poulsen; A Lerche; N T Pedersen
Journal:  Pharmacology       Date:  1985       Impact factor: 2.547

Review 8.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Oxazepam pharmacokinetics in thyroid disease.

Authors:  A K Scott; A S Khir; P D Bewsher; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

10.  Paracetamol pharmacokinetics in thyroid disease.

Authors:  J C Forfar; A Pottage; A D Toft; W J Irvine; J A Clements; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

View more
  1 in total

Review 1.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.